NASDAQ:BOLT • US0977022039
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BOLT BIOTHERAPEUTICS INC (BOLT).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-15 | Lake Street | Maintains | Buy -> Buy |
| 2025-05-20 | Lake Street | Initiate | Buy |
| 2025-05-13 | Stifel | Maintains | Hold -> Hold |
| 2025-03-25 | Stifel | Maintains | Hold -> Hold |
| 2025-03-25 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-11-13 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-08-15 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-05-15 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-05-15 | Jones Trading | Downgrade | Buy -> Hold |
| 2024-05-15 | Guggenheim | Downgrade | Buy -> Neutral |
| 2024-05-15 | Stifel | Downgrade | Buy -> Hold |
| 2024-05-15 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-03-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-03 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-06-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-26 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-05-12 | SVB Leerink | Upgrade | Market Perform -> Outperform |
| 2023-05-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-30 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-01-24 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-10-04 | HC Wainwright & Co. | Initiate | Buy |
| 2022-08-11 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2022-05-17 | Morgan Stanley | Maintains | Equal-Weight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 7.876M 37.45% | 7.69M -2.36% | 7.695M 0.07% | 3.06M -60.23% | 7.14M 133.33% | 8.16M 14.29% | 25.5M 212.50% | 25.5M | -100.00% | ||
| EBITDA YoY % growth | -74.342M 16.14% | -66.455M 10.61% | -33.342M 49.83% | -138.759M -316.17% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -76.196M 15.64% | -68.236M 10.45% | -34.633M 49.25% | -39.502M -14.06% | -38.505M 2.52% | -45.135M -17.22% | -57.421M -27.22% | -54.938M 4.33% | 225.93M 511.25% | N/A | |
| Operating Margin | -967.45% | -887.33% | -450.07% | -1,290.92% | -539.29% | -553.13% | -225.18% | -215.44% | N/A | N/A | |
| EPS YoY % growth | -36.60 22.46% | -30.40 16.94% | -17.82 41.38% | -21.85 -22.61% | -40.39 -84.87% | -43.46 -7.60% | -20.65 52.49% | -19.77 4.25% | 2.58 113.05% | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -2.91 49.88% | -2.85 36.19% | -2.31 38.03% | -1.92 50.06% |
| Revenue Q2Q % growth | 1.53M 25.20% | 1.53M -15.19% | 1.53M -29.46% | 1.53M -38.80% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -6.617M 45.48% | -6.5M 29.42% | -6.389M 17.05% | -6.282M -12.08% |
All data in USD
10 analysts have analysed BOLT and the average price target is 29.58 USD. This implies a price increase of 520.13% is expected in the next year compared to the current price of 4.77.
BOLT BIOTHERAPEUTICS INC (BOLT) will report earnings on 2026-05-11.
The consensus EPS estimate for the next earnings of BOLT BIOTHERAPEUTICS INC (BOLT) is -2.91 USD and the consensus revenue estimate is 1.53M USD.
The expected long term growth rate for BOLT BIOTHERAPEUTICS INC (BOLT) is 15.95%.